Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population

It can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-19 vaccination intentions, although evidence is scarce. In this large and representative survey of 6007 adults aged 18–64 years and residing in France, 8.1% (95% CI, 7.5–8.8) reported a prior SARS-CoV-2 infection...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fanny Velardo, Verity Watson, Pierre Arwidson, François Alla, Stéphane Luchini, Michaël Schwarzinger, CoVaMax Study Group
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 mass vaccination anti-vaccination behavior vaccine hesitancy survey experiment Medicine R
Acceso en línea:	https://doaj.org/article/a259cc56b72c4bf3b2a4ce0cd5f41019
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a259cc56b72c4bf3b2a4ce0cd5f41019
record_format	dspace
spelling	oai:doaj.org-article:a259cc56b72c4bf3b2a4ce0cd5f410192021-11-25T19:11:39ZRegional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population10.3390/vaccines91113642076-393Xhttps://doaj.org/article/a259cc56b72c4bf3b2a4ce0cd5f410192021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1364https://doaj.org/toc/2076-393XIt can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-19 vaccination intentions, although evidence is scarce. In this large and representative survey of 6007 adults aged 18–64 years and residing in France, 8.1% (95% CI, 7.5–8.8) reported a prior SARS-CoV-2 infection in December 2020, with regional variations according to an East–West gradient (<i>p</i> < 0.0001). In participants without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was substantial, including 41.3% (95% CI, 39.8–42.8) outright refusal of COVID-19 vaccination. Taking into account five characteristics of the first approved vaccines (efficacy, duration of immunity, safety, country of the vaccine manufacturer, and place of administration) as well as the initial setting of the mass vaccination campaign in France, COVID-19 vaccine acceptance would reach 43.6% (95% CI, 43.0–44.1) at best among working-age adults without prior SARS-CoV-2 infection. COVID-19 vaccine acceptance was primarily driven by vaccine characteristics, sociodemographic and attitudinal factors. Considering the region of residency as a proxy of the likelihood of getting infected, our study findings do not support the assumption that SARS-CoV-2 infection risk is associated with COVID-19 vaccine acceptance.Fanny VelardoVerity WatsonPierre ArwidsonFrançois AllaStéphane LuchiniMichaël SchwarzingerCoVaMax Study GroupMDPI AGarticleSARS-CoV-2COVID-19mass vaccinationanti-vaccination behaviorvaccine hesitancysurvey experimentMedicineRENVaccines, Vol 9, Iss 1364, p 1364 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 mass vaccination anti-vaccination behavior vaccine hesitancy survey experiment Medicine R
spellingShingle	SARS-CoV-2 COVID-19 mass vaccination anti-vaccination behavior vaccine hesitancy survey experiment Medicine R Fanny Velardo Verity Watson Pierre Arwidson François Alla Stéphane Luchini Michaël Schwarzinger CoVaMax Study Group Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
description	It can be assumed that higher SARS-CoV-2 infection risk is associated with higher COVID-19 vaccination intentions, although evidence is scarce. In this large and representative survey of 6007 adults aged 18–64 years and residing in France, 8.1% (95% CI, 7.5–8.8) reported a prior SARS-CoV-2 infection in December 2020, with regional variations according to an East–West gradient (<i>p</i> < 0.0001). In participants without prior SARS-CoV-2 infection, COVID-19 vaccine hesitancy was substantial, including 41.3% (95% CI, 39.8–42.8) outright refusal of COVID-19 vaccination. Taking into account five characteristics of the first approved vaccines (efficacy, duration of immunity, safety, country of the vaccine manufacturer, and place of administration) as well as the initial setting of the mass vaccination campaign in France, COVID-19 vaccine acceptance would reach 43.6% (95% CI, 43.0–44.1) at best among working-age adults without prior SARS-CoV-2 infection. COVID-19 vaccine acceptance was primarily driven by vaccine characteristics, sociodemographic and attitudinal factors. Considering the region of residency as a proxy of the likelihood of getting infected, our study findings do not support the assumption that SARS-CoV-2 infection risk is associated with COVID-19 vaccine acceptance.
format	article
author	Fanny Velardo Verity Watson Pierre Arwidson François Alla Stéphane Luchini Michaël Schwarzinger CoVaMax Study Group
author_facet	Fanny Velardo Verity Watson Pierre Arwidson François Alla Stéphane Luchini Michaël Schwarzinger CoVaMax Study Group
author_sort	Fanny Velardo
title	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
title_short	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
title_full	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
title_fullStr	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
title_full_unstemmed	Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population
title_sort	regional differences in covid-19 vaccine hesitancy in december 2020: a natural experiment in the french working-age population
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a259cc56b72c4bf3b2a4ce0cd5f41019
work_keys_str_mv	AT fannyvelardo regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT veritywatson regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT pierrearwidson regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT francoisalla regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT stephaneluchini regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT michaelschwarzinger regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation AT covamaxstudygroup regionaldifferencesincovid19vaccinehesitancyindecember2020anaturalexperimentinthefrenchworkingagepopulation
_version_	1718410173177921536

Regional Differences in COVID-19 Vaccine Hesitancy in December 2020: A Natural Experiment in the French Working-Age Population

Ejemplares similares